when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

calendar

7,355 catalysts · 4,728 grant · 3,080 8k filing · 2,627 approval · 2,156 device 510k · 1,745 device recall · 1,501 device pma

★ save view ↓export CSV

next 91 dayslessmore

MonWedFri

view

sort

soonest latest type sponsor alpha

type: approval×type: grant×from 2025-08-08×clear all

search

type

grant4,728
8k filing3,080
approval2,627
device 510k2,156
device recall1,745
device pma1,501

device adverse event

1,000

phase 2 completion172

therapy area

no tagged catalysts yet

Week of Aug 4, 2025

5

›Aug 8, 2025approval369d agoSODIUM ACETATE — FDA approvalSODIUM ACETATE

Sponsor: AMNEAL. Form: SOLUTION. Route: INTRAVENOUS

full page →SODIUM ACETATE →fda approvals ↗

›Aug 8, 2025approval369d agoHERNEXEOS (ZONGERTINIB) — FDA approvalzongertinib

Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL

full page →zongertinib →fda approvals ↗

›Aug 8, 2025approval369d agoACTEMRA (TOCILIZUMAB) — FDA approvaltocilizumab

Sponsor: GENENTECH. Form: INJECTABLE. Route: INJECTION

full page →tocilizumab →fda approvals ↗

›Aug 8, 2025approval369d agoACTEMRA (TOCILIZUMAB) — FDA approvaltocilizumab

Sponsor: GENENTECH. Form: INJECTABLE. Route: INTRAVENOUS, SUBCUTANEOUS

full page →tocilizumab →fda approvals ↗

›Aug 8, 2025approval369d agoIRON SUCROSE — FDA approvalsuccharated ferric oxide

Sponsor: SANDOZ. Form: INJECTABLE. Route: INTRAVENOUS

full page →succharated ferric oxide →fda approvals ↗

Week of Aug 11, 2025

8

›Aug 11, 2025approval366d agoDEFLAZACORT — FDA approvalAmneal Pharmaceuticals, Inc.

Sponsor: UPSHER SMITH LABS. Form: SUSPENSION. Route: ORAL

full page →fda approvals ↗

›Aug 12, 2025approval

Week of Aug 18, 2025

15

›Aug 18, 2025approval359d agoKESIMPTA (OFATUMUMAB) — FDA approvalKESIMPTA

Sponsor: NOVARTIS. Form: SOLUTION. Route: SUBCUTANEOUS

full page →KESIMPTA →fda approvals ↗

›Aug 18, 2025approval

Week of Aug 25, 2025

5

›Aug 25, 2025approval352d agoOPUVIZ (AFLIBERCEPT-YSZY) — FDA approvalOPUVIZ

Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

full page →OPUVIZ →fda approvals ↗

›Aug 26, 2025approval

Week of Sep 1, 2025

17

›Sep 2, 2025approval344d agoEPYSQLI (ECULIZUMAB-AAGH) — FDA approvalEPYSQLI

Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTION. Route: SOLUTION

full page →EPYSQLI →fda approvals ↗

›Sep 3, 2025approval

← prev

page 1 of 148

365d ago

RINVOQ (UPADACITINIB) — FDA approvalupadacitinib tartrate ER

Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →upadacitinib tartrate ER →fda approvals ↗

›Aug 14, 2025approval363d agoOTULFI (USTEKINUMAB-AAUZ) — FDA approvalOTULFI

Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

full page →OTULFI →fda approvals ↗

›Aug 14, 2025approval363d agoOTULFI (USTEKINUMAB-AAUZ) — FDA approvalOTULFI

Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

full page →OTULFI →fda approvals ↗

›Aug 14, 2025approval363d agoLAZCLUZE (LAZERTINIB MESYLATE) — FDA approvallazertinib mesylate

Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL

full page →lazertinib mesylate →fda approvals ↗

›Aug 14, 2025approval363d agoRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalamivantamab

Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

full page →amivantamab →fda approvals ↗

›Aug 15, 2025approval362d agoBYOOVIZ (RANIBIZUMAB-NUNA) — FDA approvalBYOOVIZ

Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

full page →BYOOVIZ →fda approvals ↗

›Aug 15, 2025approval362d agoWEGOVY (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

full page →fda approvals ↗

359d ago

BRIUMVI (UBLITUXIMAB-XIIY) — FDA approvalublituximab

Sponsor: TG THERAPEUTICS, INC. Form: INJECTABLE. Route: INTRAVENOUS

full page →ublituximab →fda approvals ↗

›Aug 18, 2025approval359d agoBRIUMVI (UBLITUXIMAB-XIIY) — FDA approvalublituximab

Sponsor: TG THERAPEUTICS, INC. Form: INJECTABLE. Route: INTRAVENOUS

full page →ublituximab →fda approvals ↗

›Aug 18, 2025approval359d agoTECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval(atezolizumab + hyaluronidase (human recombinant))

Sponsor: GENENTECH INC. Form: INJECTABLE. Route: INJECTION

full page →(atezolizumab + hyaluronidase (human recombinant)) →fda approvals ↗

›Aug 18, 2025approval359d agoTECENTRIQ (ATEZOLIZUMAB) — FDA approvalatezolizumab

Sponsor: GENENTECH INC. Form: INJECTABLE. Route: INJECTION

full page →atezolizumab →fda approvals ↗

›Aug 18, 2025approval359d agoVYEPTI (EPTINEZUMAB-JJMR) — FDA approvalH. Lundbeck AS

Sponsor: Lundbeck Seattle BioPharmaceuticals, Inc.. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

›Aug 19, 2025approval358d agoTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalteclistamab

Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

full page →teclistamab →fda approvals ↗

›Aug 19, 2025approval358d agoTALVEY (TALQUETAMAB-TGVS) — FDA approvaltalquetamab

Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

full page →talquetamab →fda approvals ↗

›Aug 21, 2025approval356d agoIMCIVREE (SETMELANOTIDE ACETATE) — FDA approvalsetmelanotide

Sponsor: RHYTHM. Form: SOLUTION. Route: SUBCUTANEOUS

full page →setmelanotide →fda approvals ↗

›Aug 21, 2025approval356d agoLEQEMBI (LECANEMAB-IRMB) — FDA approvallecanemab

Sponsor: EISAI INC. Form: INJECTABLE. Route: INJECTION

full page →lecanemab →fda approvals ↗

›Aug 21, 2025approval356d agoCEFAZOLIN SODIUM — FDA approvalSamson Medical Technologies LLC

Sponsor: HIKMA FARMACEUTICA. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

›Aug 21, 2025approval356d agoCEFAZOLIN SODIUM — FDA approvalSamson Medical Technologies LLC

Sponsor: HIKMA FARMACEUTICA. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

›Aug 21, 2025approval356d agoCEFAZOLIN SODIUM — FDA approvalSamson Medical Technologies LLC

Sponsor: HIKMA FARMACEUTICA. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

›Aug 22, 2025approval355d agoVONJO (PACRITINIB CITRATE) — FDA approvalpacritinib

Sponsor: SOBI. Form: CAPSULE. Route: ORAL

full page →pacritinib →fda approvals ↗

›Aug 22, 2025approval355d agoVEKLURY (REMDESIVIR) — FDA approvalremdesivir

Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: INTRAVENOUS

full page →remdesivir →fda approvals ↗

351d ago

TEPEZZA (TEPROTUMUMAB-TRBW) — FDA approvalteprotumumab

Sponsor: HORIZON THERAPEUTICS IRELAND. Form: INJECTABLE. Route: INJECTION

full page →teprotumumab →fda approvals ↗

›Aug 27, 2025approval350d agoFILSPARI (SPARSENTAN) — FDA approvalsparsentan

Sponsor: TRAVERE. Form: TABLET. Route: ORAL

full page →sparsentan →fda approvals ↗

›Aug 29, 2025approval348d agoBRIXADI (BUPRENORPHINE) — FDA approvalbuprenorphine LA

Sponsor: BRAEBURN. Form: SOLUTION, EXTENDED RELEASE. Route: SUBCUTANEOUS

full page →buprenorphine LA →fda approvals ↗

›Aug 29, 2025approval348d agoBILPREVDA (DENOSUMAB-NXXP) — FDA approvalBILPREVDA

Sponsor: SHANGHAI HENLIUS BIOTECH. Form: INJECTABLE. Route: INJECTION

full page →BILPREVDA →fda approvals ↗

343d ago

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalrisankizumab

Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INTRAVENOUS

full page →risankizumab →fda approvals ↗

›Sep 3, 2025approval343d agoSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalrisankizumab

Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INJECTION

full page →risankizumab →fda approvals ↗

›Sep 3, 2025approval343d agoVIGAFYDE (VIGABATRIN) — FDA approvalPyros Pharmaceuticals Inc.

Sponsor: PYROS PHARMS. Form: SOLUTION. Route: ORAL

full page →fda approvals ↗

›Sep 3, 2025approval343d agoVIGAFYDE (VIGABATRIN) — FDA approvalPyros Pharmaceuticals Inc.

Sponsor: PYROS PHARMS. Form: SOLUTION. Route: ORAL

full page →fda approvals ↗

›Sep 3, 2025approval343d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

Sponsor: RUBICON RESEARCH. Form: TABLET. Route: ORAL

full page →tramadol hydrochloride ER →fda approvals ↗

›Sep 3, 2025approval343d agoRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalamivantamab

Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

full page →amivantamab →fda approvals ↗

›Sep 5, 2025grant341d agoEVOQUANT LLC — Leveraging Large Scale Bioinformatics and AI for Natural Product Drug Discove...

AT grant. $306,872. PI: Chase Madison Clark

full page →nih reporter ↗

›Sep 5, 2025grant341d agoPERFUSION SOLUTIONS, INC. — A Fail Safe, High Output Failing Fontan Pump

HL grant. $320,838. PI: WILLIAM A SMITH

full page →nih reporter ↗

›Sep 5, 2025grant341d agoUNIVERSITY OF CALIFORNIA LOS ANGELES — Understanding Mechanisms Driving Poor Outcomes in Women with DermatomyositisUniversity of California Los Angeles

AR grant. $366,639. PI: Christina Charles-Schoeman

full page →nih reporter ↗

›Sep 5, 2025grant341d agoUNIVERSITY OF PENNSYLVANIA — Development of Dual-Action Nanoparticle-Loaded Microparticles for Osteoarthri...University of Pennsylvania

AR grant. $646,506. PI: Zhiliang Cheng

full page →nih reporter ↗

›Sep 5, 2025grant341d agoBOSTON CHILDREN'S HOSPITAL — Mental and Behavioral Health Among Vulnerable Adolescents and Young Adults in...Boston Children's Hospital

HD grant. $787,154. PI: Sabra L. Katz-Wise

full page →nih reporter ↗

›Sep 5, 2025grant341d agoUNIVERSITY OF ALABAMA AT BIRMINGHAM — Resource Core

HD grant. $236,547. PI: Hui-Ju Young

full page →nih reporter ↗

›Sep 5, 2025grant341d agoSCRIPPS RESEARCH INSTITUTE, THE — in vivo modeling of IgH-reprogrammed B cells in mice

HL grant. $647,573. PI: James Even Voss

full page →nih reporter ↗

›Sep 5, 2025grant341d agoUT SOUTHWESTERN MEDICAL CENTER — Project 2: Hepatocyte-targeted HCC chemoprevention with Anillin knockdown

CA grant. $425,304. PI: Hao Zhu

full page →nih reporter ↗

›Sep 5, 2025grant341d agoUNIVERSITY OF PENNSYLVANIA — A mixed methods approach to understanding dementia caregiver stress when cari...University of Pennsylvania

NR grant. $52,538. PI: Lauren Anne Fisher

full page →nih reporter ↗

›Sep 5, 2025grant341d agoUNIVERSITY OF CALIFORNIA, SAN FRANCISCO — Bridging the Gap Between Prediction and Reality in Structural BiologyUniversity of California San Francisco

GM grant. $501,000. PI: James M Holton

full page →nih reporter ↗

$AMRX17.88-1.43%

$NVS156.79+0.29%

$AMRX17.88-1.43%

$RYTM115.48-0.13%

$GILD133.06-0.11%

$TGTX49.16-1.21%

$TGTX49.16-1.21%

$ABBV247.97+0.78%

$ABBV247.97+0.78%

$TVTX60.89-0.70%

$ABBV247.97+0.78%